A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of SNDX-6352 in Subjects with Active Chronic Graft Versus Host Disease who have Received at least 2 Lines of Prior Therapy, i
|Effective start/end date||9/1/18 → 8/30/22|
- SYNDAX PHARMACEUTICALS
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.